ArticleJCO precision oncology2025
Exploring the Role of LINC00115 in Esophageal Squamous Cell Carcinoma: Insights Into JAK1/STAT3 Pathway Activation and Metastatic Potential.
Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEsophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy with poor prognosis. This study aims to explore the molecular mechanisms underlying ESCC metastasis, particularly focusing on the role of the long noncoding RNA LINC00115, its interaction with the KHSRP protein, and the activation of the JAK1/STAT3 signaling pathway. MATERIALS AND
methodsExpression levels of LINC00115 were analyzed in 96 paired ESCC tumor and adjacent normal tissues using RT-qPCR. In vitro assays, including CCK-8, colony formation, wound healing, Transwell migration, and invasion assays, were performed on ESCC cell lines to assess the functional impact of LINC00115. In vivo experiments were conducted using nude mouse models to evaluate the tumorigenic and metastatic potential of LINC00115. RNA pull-down, mass spectrometry, and RNA immunoprecipitation assays were used to identify and validate LINC00115 interaction partners. The involvement of the JAK1/STAT3 signaling pathway was confirmed through qPCR and Western blot analysis.
resultsLINC00115 was found to be upregulated in ESCC tissues and associated with advanced TNM staging and lymph node metastasis. Its silencing appeared to suppress ESCC cell proliferation, migration, and invasion in vitro and reduce tumor growth and metastasis in vivo. Mechanistically, LINC00115 may interact with KHSRP in the cytoplasm and potentially activate the JAK1/STAT3 signaling pathway involved in ESCC progression.
conclusionThis study suggests that LINC00115 may promote ESCC progression via the JAK1/STAT3 pathway through KHSRP interaction. Further validation is needed, and it should be considered a candidate marker rather than a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.